Show simple item record

dc.contributor.authorPatel, PHen_US
dc.contributor.authorPalma, Den_US
dc.contributor.authorMcDonald, Fen_US
dc.contributor.authorTree, ACen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-06-24T08:56:32Z
dc.date.issued2019-06-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31182289en_US
dc.identifierS0936-6555(19)30207-9en_US
dc.identifier.citationClin Oncol (R Coll Radiol), 2019en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3270
dc.identifier.eissn1433-2981en_US
dc.identifier.doi10.1016/j.clon.2019.05.015en_US
dc.description.abstractOligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease. In the era of well-tolerated targeted treatments, resistance inevitably occurs and overcoming this is a challenge. Local ablative therapy for oligoprogressive disease may allow the continuation of systemic treatments by overcoming the few sub-clones that have developed resistance. Stereotactic body radiotherapy is now frequently used in treating oligometastatic disease using ablative doses with minimally invasive techniques and acceptable toxicity. We discuss the current retrospective clinical evidence base supporting the use of local ablative therapy for oligoprogression in metastatic patients on targeted treatments within multiple tumour sites. As there is currently a lack of published prospective data available, the best management for these patients remains unclear. We discuss current trials in recruitment and the potential advancements in treating this group of patients with stereotactic radiotherapy.en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectOligometastasesen_US
dc.subjectmetastatic diseaseen_US
dc.subjectoligoprogressionen_US
dc.subjectstereotactic body radiotherapyen_US
dc.subjecttargeted therapyen_US
dc.titleThe Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?en_US
dc.typeJournal Article
dcterms.dateAccepted2019-04-17en_US
rioxxterms.versionofrecord10.1016/j.clon.2019.05.015en_US
rioxxterms.licenseref.startdate2019-06-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Oncol (R Coll Radiol)en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.publication-statusPublished onlineen_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorTree, Alisonen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/